Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tech Swerve LLC is currently handling 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. IVANOVA, SVETLANA M is the busiest examiner, holding 1 pending action. This distribution shows that each pending action is being reviewed by a different individual in a different administrative group, indicating no overlap in the current prosecution pipeline.
For the patent practitioner, the presence of 2 distinct examiners and 2 distinct art units for only 2 pending actions means that there is no opportunity to consolidate efforts with a single examiner. Each case must be argued on its own merits without the benefit of a single examiner overseeing multiple related applications. While IVANOVA, SVETLANA M is the busiest examiner with 1 pending action, this is equal to the workload of the other examiner involved. This lack of concentration across the 2 pending office actions suggests that the technology being patented may be diverse enough to trigger assignments to different specialized units within the USPTO. Practitioners must manage separate dialogues within the Biotechnology & Pharmaceuticals field, each tailored to a unique examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.8% |
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18608359 | TOPICAL TREATMENT OF HERPES INFECTIONS | JAVANMARD, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18747190 | PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE | IVANOVA, SVETLANA M | — |
| 18608359 | TOPICAL TREATMENT OF HERPES INFECTIONS | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18747190 | PENETRATING TOPICAL PAIN RELIEF COMPOSITIONS AND METHODS OF USE | IVANOVA, SVETLANA M | 1627 | §103DP | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18608359 | TOPICAL TREATMENT OF HERPES INFECTIONS | JAVANMARD, SAHAR | 1622 | §102§103Other | Non-Final OA | — | Pending | Mar 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTech Swerve LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Svetlana M Ivanova has the most, with 1 of Tech Swerve LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
